Federated Hermes Inc. Sells 135,641 Shares of Takeda Pharmaceutical Co. $TAK

Federated Hermes Inc. lowered its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 25.4% in the third quarter, HoldingsChannel.com reports. The fund owned 398,386 shares of the company’s stock after selling 135,641 shares during the quarter. Federated Hermes Inc.’s holdings in Takeda Pharmaceutical were worth $5,832,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently made changes to their positions in TAK. Royal Bank of Canada raised its position in shares of Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock valued at $6,558,000 after buying an additional 43,706 shares in the last quarter. AQR Capital Management LLC raised its stake in Takeda Pharmaceutical by 43.6% in the first quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock valued at $2,911,000 after purchasing an additional 59,442 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after purchasing an additional 692,404 shares during the period. Focus Partners Wealth grew its stake in Takeda Pharmaceutical by 4.1% during the first quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock worth $1,230,000 after buying an additional 3,239 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new position in Takeda Pharmaceutical in the 2nd quarter valued at about $351,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

NYSE:TAK opened at $17.49 on Tuesday. The stock’s 50-day moving average is $15.47 and its 200-day moving average is $14.83. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $17.55. The company has a current ratio of 1.19, a quick ratio of 0.65 and a debt-to-equity ratio of 0.56. The stock has a market cap of $55.64 billion, a P/E ratio of 72.86 and a beta of 0.02.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, January 29th. The company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.07). The business had revenue of $7.76 billion for the quarter, compared to analyst estimates of $7.81 billion. Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%. Equities research analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on TAK shares. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Finally, Morgan Stanley started coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating for the company. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Takeda Pharmaceutical currently has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.